netFormulary

Lancashire and South Cumbria
Formulary

6 Endocrine system

06-04-01-01 Oestrogens and HRT

Information is providided on the available preparations. The choice of preparation (tablet,
patch, gel) remains with the prescriber, taking into consideration patient preference and cost effectiveness.

Combined continuous HRT patch

Formulary

Evorel Conti and FemSeven Conti

The suitability of patches may be considered following discussions about safety, efficacy and other patient factors (e.g. comorbidities, adherence).

MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping

Combined continuous HRT tablet Femoston Conti

Formulary

Tablets Estradiol 1mg/Dygesterone 5mg

Combined therapy for women with uterus or endometriosis post hysterectomy

MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping

Combined cyclical HRT patch

Formulary

The suitability of patches may be considered following discussions about safety, efficacy and other patient factors (e.g. comorbidities, adherence).

MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping

Combined cyclical HRT tablet

Formulary

MHRA: Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping

Estradiol / progesterone� Bijuve

Formulary

Bijuve® is an alternative when other HRT treatments have not been tolerated or when Femoston-Conti® is being considered OR
> Bijuve replaces HRT regimens where separate oestrogen and micronised progesterone are used (single hormone products used in combination are more expensive than Bijuve®).